HOME >> MEDICINE >> NEWS
Animal studies indicate new approach for treating end-stage skin and kidney cancers

New Orleans, La., March 26, 2001 Advanced skin and end-stage kidney cancer patients may have a better chance of survival with drugs developed from a new synthetic enzyme that significantly improves the effectiveness of existing interleukin-2 (IL-2) cancer therapy, based on research presented today at the American Association for Cancer Research 92nd Annual Meeting.

In animal studies conducted by researchers at the Huntsman Cancer Institute in Salt Lake City, UT, and MetaPhore Pharmaceuticals in St. Louis, MO, the synthetic enzyme M40403 showed an ability to reverse the extreme blood-pressure drop that is a common side effect of high-dosage IL-2 cancer therapy. The research also showed that the compound enhances the anti-cancer properties of IL-2 therapy.

IL-2 immunotherapy, which works by activating natural killer (NK) cells that have the ability to recognize and destroy many types of tumors, is an approved treatment for inoperable metastatic melanoma and metastatic renal cell carcinoma. About 80,000 cases of melanoma and renal cell carcinoma are diagnosed in the U.S. each year.

IL-2 use is limited, however, by potentially life threatening side effects, including hypotension, particularly at the high-dosage level indicated for these end-stage cancers. A majority of patients undergoing high-dosage IL-2 treatment currently either require intensive care unit (ICU) intervention and/or are unable to complete the full course of treatment.

Reseachers administered the synthetic enzyme, which mimics the action of a natural enzyme, superoxide dismutase (SOD), as a co-therapy with IL-2 in several animal models of advanced cancer. Previous studies have confirmed that the synthetic enzyme effectively reproduces the free-radical fighting properties of the natural SOD enzyme, which has been found to be deficient in cancer states.

When in excess, free radicals particularly superoxide anions have been shown to deactivate a class of molecules, calle
'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
25-Mar-2001


Page: 1 2 3 4

Related medicine news :

1. Animal study shows link between nicotine and atrial flutter
2. Animal studies show stem cells might make biological pacemaker
3. Animal study suggests safer immunization approach to Alzheimers
4. Animal model, new grant, propel UB researchers forward in search for tinnitus treatment
5. Animal model shows early promise for SARS vaccine
6. Understanding Alzheimers disease: Animal research points to new direction for therapy
7. Animal studies prove hormone replacement therapy improves memory, report Pitt researchers
8. Animal-based nutrients linked with higher risk of stomach and esophageal cancers
9. Animal study show that heat-sensitive liposome improves chemotherapy delivery to tumors
10. Animal model shows pain and tissue injury in newborns alters nerve circuitry and reaction to pain later in life
11. AVANT Atherosclerosis Vaccine Raises HDL, Reduces Atherosclerosis In Vaccinated Animals

Post Your Comments:
(Date:7/23/2014)... Recently, Agebc.com has launched its new ... is announcing a promotion of wedding dresses. According to ... at the end of this month. , The beautiful ... like A-line, mermaid, ball-gown, empire, and more. Agebc.com is ... special-occasion dresses for women, and the company is devoted ...
(Date:7/23/2014)... Adipic acid is an intermediate chemical ... plastic, often referred to as engineering thermoplastics. These ... the monomers employed. Due to the high production ... increasing number of developing countries, the Asia-Pacific region ... by Europe and North America. Adipic acid in ...
(Date:7/23/2014)... The European Vitamins Market report explains and divides ... of revenue. The market in Europe is estimated to ... million by 2018, at a CAGR of 6.8% from ... the European Vitamins Market report, to get an idea ... glimpse of the segmentation in the European market, and ...
(Date:7/23/2014)... Texas (PRWEB) July 23, 2014 ... 2020?, provides key market data on the North ... value, in millions of US dollars, and volume ... dollars), within market categories Cardiac Valve Repairs and ... shares and distribution shares data for each of ...
(Date:7/23/2014)... who suffered repeated blows to the head during their ... clumps suggest the athletes had a disease called chronic ... that might be able to detect CTE in its ... & Engineering News (C&EN) , the weekly news magazine ... Lauren Wolf, a senior editor at C&EN, explains that ...
Breaking Medicine News(10 mins):Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 2Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 3Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 4Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 5
(Date:7/23/2014)... YORK , July 23, 2014  Dompe, a leader ... rare diseases, announces that rhNGF (Recombinant Human Nerve Growth Factor) ... Food and Drug Administration (FDA). The candidate ... as an orphan drug for the treatment of neurotrophic keratitis, ... 5,000 people 1 and is currently without a cure. ...
(Date:7/23/2014)... July 23, 2014  ArmaGen, a privately held ... treat severe neurological disorders, announced today that it ... agreement with Shire plc to develop AGT-182, an ... of both the central nervous system (CNS) and ... as MPS II, Hunter syndrome is a rare, ...
(Date:7/23/2014)... July 23, 2014 ... Arbeiten für Sadara Chemical Company (Sadara) erhalten ... System innerhalb des integrierten Chemiekomplexes von Sadara ... additional scope im Wert von mehreren Millionen ... Vertrags dar, dessen Wert sich ebenfalls auf ...
Breaking Medicine Technology:Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 4
Cached News: